Interview: Revolution At GSK India
This article was originally published in Scrip
Executive Summary
Brace for GSK India's new avatar. The British multinational is revamping its business model in India and donning a new approach to create, deliver and capture value via a "one team" effort as it strives to emerge as the fastest growing pharma multinational in the country by 2020.
You may also be interested in...
GSK India Chief On Pandemic Decisions, Refreshing The Portfolio
GSK India managing director Sridhar Venkatesh outlines how the company navigated pandemic-related turbulence and “stuck its neck out” to ensure uninterrupted supplies of key drugs. The executive also discusses launch prospects for products including Xevudy in India and an intent to “refresh” the company’s vaccines portfolio.
GSK India Chief On Pandemic Decisions, Refreshing The Portfolio
GSK India managing director Sridhar Venkatesh outlines how the company navigated pandemic-related turbulence and “stuck its neck out” to ensure uninterrupted supplies of key drugs. The executive also discusses launch prospects for products including Xevudy in India and an intent to “refresh” the company’s vaccines portfolio.
GSK Resetting Old And Building New Product Planks In India
GlaxoSmithKline is looking to rebuild in India its topical antibiotic brand Neosporin, which has returned to the market after an almost two-year absence following supply issues, while a new - seemingly India-specific - thrust in prescription probiotics and momentum in vaccines are also seen driving local growth this year.